ZORYANA STOYKO M.D.
Prescription History 1346689049
Internal Medicine - Hematology & Oncology in Northfield, NJ


Quality Rating: 89.79 out of 100 score

NPI Status: Active since June 17, 2013

Contact Information

411 NEW RD
NORTHFIELD, NJ
ZIP 08225
Phone: (609) 383-6033
Fax: (609) 383-1548

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ZORYANA STOYKO M.D., an active Hematology & Oncology specialist practicing in Northfield, NJ. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 248 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 51 claims alone.


Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 25.0
Days Supply 750
NJ State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills161.6
Peer Average Days Supply4,810
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.1% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $216.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.66

State Avg Cost Per Claim

$29.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Brukinsa

Generic Formulation: ZanubrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
NJ State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply915
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $275,376.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,298.69

State Avg Cost Per Claim

$13,814.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 51
30-Day Fills 70.0
Days Supply 2,100
NJ State Average Benchmarks
Peer Average Claims82.0
Peer Average 30-Day Fills136.9
Peer Average Days Supply3,816
Conservative Utilization

This provider writes prescriptions for this formulation 37.8% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $42,224.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$827.93

State Avg Cost Per Claim

$837.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 450
NJ State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills109.8
Peer Average Days Supply3,196
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.5% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $133.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.93

State Avg Cost Per Claim

$19.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 15
30-Day Fills 38.8
Days Supply 1,164
NJ State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills60.3
Peer Average Days Supply1,775
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $873.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.25

State Avg Cost Per Claim

$42.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 44
30-Day Fills 111.0
Days Supply 3,315
NJ State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills113.5
Peer Average Days Supply3,374
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,321.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.04

State Avg Cost Per Claim

$31.85

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 342
NJ State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills35.1
Peer Average Days Supply320
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $480.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.49

State Avg Cost Per Claim

$17.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 365
NJ State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills66.8
Peer Average Days Supply1,455
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.5% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $586.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.33

State Avg Cost Per Claim

$30.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Verzenio

Generic Formulation: AbemaciclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 23.4
Days Supply 490
NJ State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.5
Peer Average Days Supply653
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $287,069.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,948.30

State Avg Cost Per Claim

$13,749.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer. Abemaciclib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Warfarin Sodium

Generic Formulation: Warfarin SodiumSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 37.0
Days Supply 1,110
NJ State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills81.5
Peer Average Days Supply2,226
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.5% less volume than the regional standard for practitioners inside NJ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $414.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.88

State Avg Cost Per Claim

$13.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Therapeutic Applications

This medication is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement). Warfarin is commonly called a blood thinner, but the more correct term is anticoagulant. It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ZORYANA STOYKO M.D. provides transparency into local medical care patterns within Northfield, NJ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.